Peptides: BPC-157 + TB-500 Stack Protocol
BPC-157 acts locally via NO pathway and VEGF; TB-500 distributes systemically via actin sequestration. Combined, they target different aspects of tissue repair.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | C | grade | Stack combination — no direct human studies; extrapolated from separate animal studies on each peptide |
| BPC-157 Dose | 200–400 | mcg/dose | Injected subcutaneously near injury site; once or twice daily; route and location matter for local effect |
| TB-500 Loading Dose | 5–10 | mg/week | Systemic subcut injection; split as two weekly doses; covers areas BPC-157 may not reach locally |
| Cycle Duration | 8–12 | weeks | Typical stack cycle; 4 weeks minimum off-cycle; adjust based on injury resolution |
| Combined Angiogenesis Effect | Additive | theoretical | Both peptides promote VEGF-mediated angiogenesis via different upstream pathways (animal study) |
| BPC-157 Distribution | Local | mechanism | Works best when injected near injury site; systemic effects less pronounced than TB-500 |
| TB-500 Distribution | Systemic | mechanism | Distributes body-wide regardless of injection site; complements BPC-157's local action |
The BPC-157 and TB-500 stack combines two peptides with complementary mechanisms: BPC-157 provides targeted local tissue repair, while TB-500 delivers systemic coverage. Neither has been studied in humans as a stack — all evidence is from separate animal studies on each compound (PMID 36144773; PMID 22165960; PMID 33237028). (animal study) The rationale is mechanistic, not clinical.
Mechanism Comparison
| Mechanism | BPC-157 | TB-500 | Combined Effect (Theoretical) |
|---|---|---|---|
| Primary mechanism | NO-pathway modulation, VEGF induction | G-actin sequestration, cell migration | Complementary: different upstream triggers |
| Receptor/pathway | Nitric oxide synthase; VEGFR | Thymosin beta-4 receptor; VEGFR | Both converge on VEGF-driven angiogenesis |
| Distribution pattern | Local — injection site concentration | Systemic — body-wide distribution | Local + systemic coverage |
| Angiogenesis | Yes — VEGF-mediated (animal study) | Yes — VEGF + actin remodeling (animal study) | Additive angiogenic stimulus |
| Collagen synthesis | Yes — promotes fibroblast recruitment | Yes — cell migration facilitates matrix repair | Potentially additive collagen remodeling |
| Anti-inflammatory | Yes — reduces pro-inflammatory cytokines | Yes — reduces IL-1β, TNF-α (animal study) | Complementary anti-inflammatory coverage |
| Neurological effects | Yes — GABAergic and dopaminergic modulation | Limited — primarily peripheral tissue | BPC-157 dominant for neurological applications |
| Evidence grade | C (animal/in vitro primarily) | C (animal/in vitro primarily) | C (theoretical stack, no direct studies) |
Combined Protocol Reference Card
| Peptide | Dose | Frequency | Route | Cycle | Timing Notes |
|---|---|---|---|---|---|
| BPC-157 | 200–400mcg | Once or twice daily | Subcut near injury site | 8–12 weeks on | Inject as close to injury as practical; some benefit from oral route for gut issues |
| TB-500 | 5mg (loading) | Twice weekly | Subcut — abdomen/flank | Weeks 1–6 | Site does not need to be near injury; systemic distribution |
| TB-500 | 2–2.5mg (maintenance) | Once weekly | Subcut | Weeks 7–12 | After acute phase, taper to maintenance |
| Off-cycle | — | — | — | 4+ weeks minimum | Allow receptor sensitivity to reset; assess injury resolution before repeating |
When to Consider the Stack vs. BPC-157 Alone
Use BPC-157 alone when: the injury is localized (e.g., single tendon, specific gut segment), cost is a concern, or a targeted local approach is preferred.
Consider adding TB-500 when: injuries are diffuse or multiple, systemic inflammation is present, the injury site is difficult to inject directly, or BPC-157 alone has produced incomplete results after 4+ weeks.
Legal Status
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | Both research chemicals | Neither scheduled | Both WADA prohibited (S2); not FDA-approved |
| UK | Neither scheduled | None | Legal to possess; both WADA prohibited for athletes |
| Australia | Both restricted | Both Schedule 4 (TGA) | Both ASADA prohibited for competitive athletes |
| Canada | Both gray market | No schedule | No approved DINs; both WADA prohibited |
| EU | Both generally unscheduled | Varies by country | Not harmonized; both WADA prohibited |
Cost Consideration
TB-500 is significantly more expensive per cycle than BPC-157 due to higher per-dose weight requirements. A standard loading cycle of TB-500 (10mg/week × 6 weeks = 60mg) costs roughly 3–5× more than a comparable BPC-157 cycle at 400mcg/day × 6 weeks = ~16.8mg total. Budget planning is relevant when deciding whether the systemic coverage justifies the added cost.
Related Pages
Sources
- Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. 2022. PMID 36144773
- Goldstein AL et al. Thymosin beta-4 promotes angiogenesis, wound healing, and hair follicle development. Ann N Y Acad Sci. 2012. PMID 22165960
- Peplow PV. Actions of thymosin beta-4 against chronic inflammation, vascular injury. Neural Regen Res. 2021;16(11):2211-2218. PMID 33237028
Frequently Asked Questions
Is there any human evidence for the BPC-157 + TB-500 combination?
No. There are currently no published human studies examining the combination of BPC-157 and TB-500. All rationale for stacking is extrapolated from separate animal studies on each peptide individually (PMID 36144773; PMID 22165960). The combination is used by practitioners based on mechanistic reasoning, not clinical trial data.
Can BPC-157 and TB-500 be injected at the same time?
They can be injected in separate syringes at the same session, but should not be mixed in the same syringe due to differences in peptide stability and pH. BPC-157 is typically injected subcutaneously near the injury site, while TB-500 is injected subcutaneously at a convenient systemic site such as the abdomen.
How does the BPC-157 + TB-500 stack differ from using BPC-157 alone?
BPC-157 alone provides local tissue repair via NO-pathway modulation and VEGF upregulation at the injection site. Adding TB-500 extends coverage systemically — useful for multiple injury sites, systemic inflammation, or conditions where the precise injury location is diffuse. TB-500 also contributes actin-remodeling effects that BPC-157 does not directly address.